J&J rivaroxaban (correction)
Johnson & Johnson is developing the anticoagulant as an oral product only, not in multiple formulations. In a recent analyst update, the company suggested the product would offer an advantage in that the oral agent can be used both in the hospital and then later in the home (1"The Pink Sheet" June 11, 2007, p. 19)...
You may also be interested in...
Johnson & Johnson's next generation non-nucleoside reverse transcriptase inhibitor TMC 125 is on deck to be the first of the firm's four virology NDAs over the next four years, Group Chairman Julie McHugh said during an analyst update outlining the company's growth strategy in New Brunswick, N.J. June 7
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.